AU2022394333A1 - HTT modulators for treating Huntington’s disease - Google Patents

HTT modulators for treating Huntington’s disease Download PDF

Info

Publication number
AU2022394333A1
AU2022394333A1 AU2022394333A AU2022394333A AU2022394333A1 AU 2022394333 A1 AU2022394333 A1 AU 2022394333A1 AU 2022394333 A AU2022394333 A AU 2022394333A AU 2022394333 A AU2022394333 A AU 2022394333A AU 2022394333 A1 AU2022394333 A1 AU 2022394333A1
Authority
AU
Australia
Prior art keywords
alkyl
mmol
compound
methyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022394333A
Other languages
English (en)
Inventor
Mark Chambers
Cole Clissold
Brett COSGROVE
Celia Dominguez
William ESMIEU
Alan Haughan
Longbin Liu
Karine Malagu
Nikolay V. PLOTNIKOV
Jonathan Spencer
Andrew STOTT
Huw VATER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHDI Foundation
Original Assignee
CHDI Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHDI Foundation filed Critical CHDI Foundation
Publication of AU2022394333A1 publication Critical patent/AU2022394333A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022394333A 2021-11-17 2022-11-16 HTT modulators for treating Huntington’s disease Pending AU2022394333A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280551P 2021-11-17 2021-11-17
US63/280,551 2021-11-17
PCT/US2022/050058 WO2023091456A1 (en) 2021-11-17 2022-11-16 N-(2h-indazol-5-yl)pyrazine-2-carboxamide derivatives and similar compounds as htt modulators for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
AU2022394333A1 true AU2022394333A1 (en) 2024-06-27

Family

ID=84602418

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022394333A Pending AU2022394333A1 (en) 2021-11-17 2022-11-16 HTT modulators for treating Huntington’s disease

Country Status (10)

Country Link
US (1) US12281116B2 (cg-RX-API-DMAC7.html)
EP (1) EP4433471A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024540477A (cg-RX-API-DMAC7.html)
KR (1) KR20240115832A (cg-RX-API-DMAC7.html)
CN (1) CN118510769A (cg-RX-API-DMAC7.html)
AU (1) AU2022394333A1 (cg-RX-API-DMAC7.html)
CA (1) CA3238090A1 (cg-RX-API-DMAC7.html)
IL (1) IL312891A (cg-RX-API-DMAC7.html)
MX (1) MX2024005933A (cg-RX-API-DMAC7.html)
WO (1) WO2023091456A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298941A (en) 2020-06-11 2023-02-01 Chdi Foundation Inc Heterocyclic compounds and imaging agents for the imaging of huntingtin protein

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7531558B2 (en) 2003-02-14 2009-05-12 Glaxo Group Limited Carboxamide derivatives
WO2005016928A1 (ja) 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
JP2007518816A (ja) * 2004-01-23 2007-07-12 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
JP2007051121A (ja) * 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンd合成酵素を阻害するピリミジン化合物
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
AU2008245082B8 (en) 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
CA2913785C (en) 2013-06-25 2021-08-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
JP6521995B2 (ja) 2014-02-20 2019-05-29 ユニヴァーシティー オブ ノートル ダム デュ ラック 選択的マトリックスメタロプロテイナーゼ阻害剤
MX375925B (es) 2014-06-25 2025-03-07 Hoffmann La Roche Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
WO2016187544A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cancer
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩
JP2019535789A (ja) 2016-11-28 2019-12-12 ピーティーシー セラピューティクス,インコーポレーテッド Rnaスプライシングを調節する方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
MX2020001425A (es) 2017-08-04 2020-08-06 Skyhawk Therapeutics Inc Metodos y composiciones para modular el empalme.
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113660936A (zh) 2019-02-04 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP2022519637A (ja) 2019-02-04 2022-03-24 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
JP2022519296A (ja) 2019-02-04 2022-03-22 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
EP3920918A4 (en) 2019-02-05 2022-11-16 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
WO2020163401A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163406A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102913697B1 (ko) 2019-02-05 2026-01-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102925385B1 (ko) 2019-02-06 2026-02-11 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
JP7603594B2 (ja) 2019-02-06 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
AU2020222881C1 (en) 2019-02-13 2026-01-22 Ptc Therapeutics, Inc. Thioeno(3,2-b) pyridin-7-amine compounds for treating familial dysautonomia
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
TW202131920A (zh) 2019-11-01 2021-09-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
AU2021228285A1 (en) 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CA3169697A1 (en) 2020-02-28 2021-09-02 Dominic Reynolds Thiophenyl derivatives useful for modulating nucleic acid splicing
AU2021228284A1 (en) 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CA3169667A1 (en) 2020-02-28 2021-09-02 Dominic Reynolds Pyridazine derivatives for modulating nucleic acid splicing
CA3174353A1 (en) 2020-04-08 2021-10-14 Dominic Reynolds Compounds and methods for modulating splicing
MX2022012677A (es) 2020-04-08 2023-01-11 Remix Therapeutics Inc Compuestos y metodos para modular el empalme.
MX2022012575A (es) 2020-04-09 2023-01-24 Ptc Therapeutics Inc Compuestos para usarse para tratar la enfermedad de huntington.
WO2021231571A1 (en) 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease

Also Published As

Publication number Publication date
US12281116B2 (en) 2025-04-22
WO2023091456A1 (en) 2023-05-25
JP2024540477A (ja) 2024-10-31
US20230159531A1 (en) 2023-05-25
IL312891A (en) 2024-07-01
CA3238090A1 (en) 2023-05-25
MX2024005933A (es) 2024-08-06
CN118510769A (zh) 2024-08-16
KR20240115832A (ko) 2024-07-26
EP4433471A1 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US11806346B2 (en) HTT modulators for treating Huntington's disease
US20230303489A1 (en) Compounds, compositions and methods of use
US20230250072A1 (en) Modulators of eukaryotic initiation factor 2
US20200171029A1 (en) Biheteroaryl compounds and uses thereof
US10981900B2 (en) Spiro compound and use thereof
US20210363144A1 (en) Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor
US12551580B2 (en) Heterocyclic compounds and imaging agents for imaging Huntington protein
US12281116B2 (en) HTT modulators for treating Huntington's disease
CA3160053A1 (en) Compounds for treating familial dysautonomia
KR20260057425A (ko) 화합물, 조성물, 및 방법
AU2023259291B2 (en) Piperidine carboxamide azaindane derivative, method for preparing same, and use thereof
WO2025260014A1 (en) Compounds, compositions, and methods
HK40017092B (en) Compouns, compositions and methods of use
HK40017092A (en) Compouns, compositions and methods of use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE